Table 1.
Overview of Drug Price and National Reimbursement Negotiations in China From 2016 to 2021.
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Quantity of drugs to be negotiated | 5 | 44 | 18 | 150 | 162 | 117 |
| Number of successfully negotiated drugs | 3 | 36 | 17 | 97 | 119 | 94 |
| (first negotiated) | 3 | 36 | 17 | 70 | 96 | 67 |
| (renewal negotiation) | 27 | 23 | 27 | |||
| Negotiation success rate (%) | 60 | 82 | 94.3 | 64.7 | 73.5 | 80.3 |
| Average price reduction (%) | 59 | 44 | 57 | 61 | 51 | 62 |
| Number of anticancer drugs newly included in NRDL | 2 | 18 | 17 | 10 | 17 | 18 |
| The proportion of anticancer drugs in newly added drugs (%) | 66.7 | 50 | 100 | 14.3 | 17.7 | 26.9 |